Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience

Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19

(2022) Marco Falcone et al.   CLINICAL THERAPEUTICS

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

(2022) Jennifer Hammond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients

(2022) Ronza Najjar-Debbiny et al.   CLINICAL INFECTIOUS DISEASES

Caring for older adults during the COVID-19 pandemic

(2022) Virginie Prendki et al.   CLINICAL MICROBIOLOGY AND INFECTION

Nirmatrelvir Plus Ritonavir: First Approval

(2022) Yvette N. Lamb   DRUGS

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

(2022) Tommy Nyberg et al.   LANCET

Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study

(2022) Peter Bager et al.   LANCET INFECTIOUS DISEASES

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

(2022) Emi Takashita et al.   NEW ENGLAND JOURNAL OF MEDICINE

From Positive to Negative to Positive Again—The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid

(2022) Rita Rubin   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies

(2022) Daichi Yamasoba et al.   LANCET INFECTIOUS DISEASES

Decreased Risk of Coronavirus Disease 2019–Related Hospitalization Associated With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2

(2022) Jessica P Ridgway et al.   Open Forum Infectious Diseases

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

(2021) Florian Kabinger et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern

(2021) Marco Falcone et al.   Infectious Diseases and Therapy

What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group

(2021) Giusy Tiseo et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

(2021) Angélica Jayk Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

(2021) Robert L. Gottlieb et al.   NEW ENGLAND JOURNAL OF MEDICINE

Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports

(2021) Elisabeth Mahase   BMJ-British Medical Journal

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia

(2021) Francesco Menichetti et al.   JAMA Network Open

Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study

(2020) Marco Falcone et al.   Open Forum Infectious Diseases

Handling Time-dependent Variables: Antibiotics and Antibiotic Resistance

(2016) L. Silvia Munoz-Price et al.   CLINICAL INFECTIOUS DISEASES